Clinical Trials

Posted on

A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder that Affects the Peripheral Nerves) (ADHERE) *No Longer Recruiting*

This is a phase 2 study to evaluate the safety and efficacy of the subcutaneous formulation of efgartigimod in adults with CIDP. *No longer recruiting*

Learn more at